News

Filter

Current filters:

Basilea Pharmaceutica

1 to 9 of 14 results

FDA approves Astellas’ new antifungal drug Cresemba

FDA approves Astellas’ new antifungal drug Cresemba

07-03-2015

The US Food and Drug Administration on Friday approved Cresemba (isavuconazonium sulfate), a new antifungal…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCresembaPharmaceuticalRegulationUSA

Basilea appoints David Veitch as chief commercial officer

Basilea appoints David Veitch as chief commercial officer

19-08-2014

Switzerland-based Basilea Pharmaceutica has appointed David Veitch as its chief commercial officer.

Basilea PharmaceuticaBoardroomPharmaceuticalSwitzerland

Astellas amends license deal for isavuconazole with Basilea

01-03-2014

Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

Report looks at impact of new law governing clinical trials in Switzerland

Report looks at impact of new law governing clinical trials in Switzerland

15-11-2013

Clinical trials in Switzerland have been the subject of a new report carried out by the Swiss Federal…

Basilea PharmaceuticaEli LillyEuropeLegalNovartisPharmaceuticalResearchRoche

Astellas’ antifungal study reports positive results

30-09-2013

Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE)…

Asia-PacificAstellas PharmaBasilea PharmaceuticaDermatologicalsisavuconazolePharmaceuticalResearch

Basilea updates on isavuconazole development

17-07-2013

Switzerland-based Basilea Pharmaceutica Ltd. (SIX: BSLN) provided an update today (July 17) on the Phase…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaisavuconazolePharmaceuticalResearch

1 to 9 of 14 results

Back to top